99 related articles for article (PubMed ID: 21414687)
1. [Time-influencing factors for biochemical progression following radical prostatectomy].
Barba J; Brugarolas X; Tolosa E; Rincón A; Romero L; Rosell D; Robles JE; Zudaire JJ; Berian JM; Pascual JI
Actas Urol Esp; 2011 Apr; 35(4):201-7. PubMed ID: 21414687
[TBL] [Abstract][Full Text] [Related]
2. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
3. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
[TBL] [Abstract][Full Text] [Related]
4. Radical prostatectomy for clinical stage T3a disease.
Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
[TBL] [Abstract][Full Text] [Related]
5. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
6. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
[TBL] [Abstract][Full Text] [Related]
7. [Complete radical prostatectomy and positive lymph nodes (stages pT1 to 4, N1 to 3, M0, D1)].
Feyaerts A; Stainier L; Nollevaux MC; De Groote P; Lorge F; Opsomer R; Wese FX; Cosyns JP; Van Cangh P
Acta Urol Belg; 1998 Mar; 66(1):1-6. PubMed ID: 9611351
[TBL] [Abstract][Full Text] [Related]
8. Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up.
Menon M; Bhandari M; Gupta N; Lane Z; Peabody JO; Rogers CG; Sammon J; Siddiqui SA; Diaz M
Eur Urol; 2010 Dec; 58(6):838-46. PubMed ID: 20869162
[TBL] [Abstract][Full Text] [Related]
9. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
10. Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence.
Shikanov S; Song J; Royce C; Al-Ahmadie H; Zorn K; Steinberg G; Zagaja G; Shalhav A; Eggener S
J Urol; 2009 Jul; 182(1):139-44. PubMed ID: 19450829
[TBL] [Abstract][Full Text] [Related]
11. [Value of positive resection margins in patients with pT2 prostate cancer. Implications for adjuvant treatment].
Rosas-Nava JE; Herranz-Amo F; Paños-Fagundo EV; Lledó-García E; Verdú-Tartajo F; Hernández-Fernández C
Actas Urol Esp; 2011 May; 35(5):272-6. PubMed ID: 21397985
[TBL] [Abstract][Full Text] [Related]
12. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
13. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center.
Freedland SJ; Grubb KA; Yiu SK; Humphreys EB; Nielsen ME; Mangold LA; Isaacs WB; Partin AW
J Urol; 2005 Sep; 174(3):919-22. PubMed ID: 16093988
[TBL] [Abstract][Full Text] [Related]
14. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer.
D'Amico AV; Wu Y; Chen MH; Nash M; Renshaw AA; Richie JP
J Urol; 2001 Jan; 165(1):126-9. PubMed ID: 11125380
[TBL] [Abstract][Full Text] [Related]
15. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.
Eggener SE; Roehl KA; Smith ND; Antenor JA; Han M; Catalona WJ
J Urol; 2005 Apr; 173(4):1150-5. PubMed ID: 15758725
[TBL] [Abstract][Full Text] [Related]
16. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
17. Does prior benign prostate biopsy predict outcome for patients treated with radical perineal prostatectomy?
Raj GV; Brashears JH; Anand A; Paulson DF; Polascik TJ
Urology; 2005 Feb; 65(2):332-6. PubMed ID: 15708048
[TBL] [Abstract][Full Text] [Related]
18. Outcome and complications of radical prostatectomy in patients with PSA <10 ng/ml: comparison between the retropubic, perineal and laparoscopic approach.
Salomon L; Levrel O; Anastasiadis AG; Saint F; de La Taille A; Cicco A; Vordos D; Hoznek A; Chopin D; Abbou CC
Prostate Cancer Prostatic Dis; 2002; 5(4):285-90. PubMed ID: 12627213
[TBL] [Abstract][Full Text] [Related]
19. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
20. [Progression after radical prostatectomy of cancer of the prostate: prognostic criteria and the role of PSA in monitoring].
Fendler JP; Dujardin T; Bringeon G; Adeleine P; Devonec M; Perrin P
Prog Urol; 1992 Feb; 2(1):58-65. PubMed ID: 1284386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
